

**Synonym**

LILRB3,CD85a,ILT5

**Source**

Biotinylated Human LILRB3, Fc,Avitag (CDA-H82F6) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Glu 443 (Accession # AAI12199).

Predicted N-terminus: Gly 24

**Molecular Characterization**

LILRB3(Gly 24 - Glu 443) AAI12199	Fc(Pro 100 - Lys 330) P01857	Avi
--------------------------------------	---------------------------------	-----

This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).

The protein has a calculated MW of 74.5 kDa. As a result of glycosylation, the protein migrates as 80-105 kDa under reducing (R) condition, and 150 kDa under non-reducing (NR) condition (SDS-PAGE).

**Biotinylation**

*Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.*

**Biotin:Protein Ratio**

The biotin to protein ratio is *0.5-1* as determined by the HABA assay.

**Endotoxin**

Less than 1.0 EU per µg by the LAL method.

**Purity**

>95% as determined by SDS-PAGE.

**Formulation**

Lyophilized from 0.22 µm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

**Reconstitution**

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*


**Storage**

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

*Please avoid repeated freeze-thaw cycles.*

No activity loss was observed after storage at:

- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

**SDS-PAGE**

Biotinylated Human LILRB3, Fc,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

**Background**

Leukocyte immunoglobulin-like receptor subfamily B member 3 is also known as LILRB3,ILT-5 or CD85a. LILRB3 plays a role as receptor for class I MHC antigens, which activated upon coligation of LILRB3 and immune receptors, such as FCGR2B and the B-cell receptor. LILRB3 and LILRA6 represent a pair of inhibitory/activating receptors with identical extracellular domains and unknown ligands. LILRB3 can mediate inhibitory signaling via immunoreceptor tyrosine-based inhibition motifs in its cytoplasmic tail whereas LILRA6 can signal through association with an activating adaptor molecule, FcR $\gamma$ .

**References**

- (1) [Bashirova AA, et al., 2014, Immunogenetics.66\(1\):1-8.](#)
- (2) [Huang J., et al., 2010, J Virol. 84\(18\):9463-71.](#)
- (3) [Pfistershammer K., et al., 2009, Blood. 114\(11\):2323-32.](#)

Please contact us via [TechSupport@acrobiosystems.com](mailto:TechSupport@acrobiosystems.com) if you have any question on this product.